FLVCR2 and cancer: While CCT could fold up to 10% of the normal cell proteome, it may have a heighten role during oncogenesis, supporting the growth of cancer cells through client proteins such cytoskeletal proteins (actin, tubulin), cell cycle mediators (cell division cycle protein 20 (cdc20), cyclin E, p53, etc.)[6, 7], and growth/survival factors (Signal transducer and activator of transcription 3 (STAT3), Myelocytomatosis (MYC), etc.)[4, 8, 9].